Edoxaban

Pre-clinicalUNKNOWN

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Heart Failure

Conditions

Heart Failure

Trial Timeline

Apr 1, 2015 → Mar 1, 2016

NCT ID

NCT02448901

About Edoxaban

Edoxaban is a pre-clinical stage product being developed by Daiichi Sankyo for Heart Failure. The current trial status is unknown. This product is registered under clinical trial identifier NCT02448901. Target conditions include Heart Failure.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05804747	Pre-clinical	Completed	Feb 16, 2023	Jul 28, 2025	Atrial Fibrillation
NCT04747496	Pre-clinical	Completed	Feb 26, 2021	Nov 27, 2024	Non-valvular Atrial Fibrillation
NCT04594915	Pre-clinical	Completed	Aug 14, 2020	Jun 21, 2023	Atrial Fibrillation
NCT04519944	Pre-clinical	Completed	Jun 30, 2020	Jul 6, 2023	Non-valvular Atrial Fibrillation
NCT04171726	Phase 3	UNKNOWN	Aug 1, 2019	Sep 1, 2023	Aortic Valve Stenosis
NCT03840291	Approved	Completed	May 19, 2019	Aug 1, 2024	Atrial Fibrillation
NCT03247569	Pre-clinical	Completed	Oct 18, 2017	Feb 28, 2022	Atrial Fibrillation
NCT03247582	Pre-clinical	Completed	Aug 2, 2017	May 3, 2022	Atrial Fibrillation
NCT02952599	Pre-clinical	Completed	Mar 27, 2017	Oct 29, 2019	Venous Thromboembolism
NCT02951039	Pre-clinical	Completed	Feb 21, 2017	Oct 15, 2020	Atrial Fibrillation
NCT02964949	Pre-clinical	Completed	Jan 24, 2017	Oct 9, 2018	Atrial Fibrillation
NCT02943993	Pre-clinical	Completed	Apr 6, 2016	Dec 1, 2020	Venous Thromboembolism
NCT02944019	Pre-clinical	Completed	Aug 1, 2015	Apr 13, 2022	Atrial Fibrillation
NCT02448901	Pre-clinical	UNKNOWN	Apr 1, 2015	Mar 1, 2016	Heart Failure

Competing Products

20 competing products in Heart Failure

See all competitors

Product	Company	Stage	Hype Score
IV diuretic	Nuwellis	Pre-clinical	15
IV Loop Diuretics	Nuwellis	Pre-clinical	15
Stepped pharmacologic care	Nuwellis	Phase 3	69
IV Loop Diuretics (LD)	Nuwellis	Pre-clinical	15
TRV120027 + Normal Saline	Trevena	Phase 1	25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo	Trevena	Phase 2	44
TRV120027 + Placebo	Trevena	Phase 1/2	33
Ilofotase alfa + Placebo	AM-Pharma	Phase 2	44
INXN-4001	Precigen	Phase 1	28
LY3461767 + Placebo	Eli Lilly	Phase 1	33
SGLT2i, beta blocker, ARNI, MRA, MTD	Eli Lilly	Approved	85
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	52
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks	Daiichi Sankyo	Approved	85
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil	Daiichi Sankyo	Phase 3	77
Olmesartan	Daiichi Sankyo	Phase 3	77
Carperitide + Placebo	Daiichi Sankyo	Phase 2	52
Regadenoson	Astellas Pharma	Phase 1	33
Advagraf + Prograf	Astellas Pharma	Phase 2	52
FK506E	Astellas Pharma	Phase 3	77
Conivaptan	Astellas Pharma	Approved	85

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved

OAC aloneApproved

olmesartan medoxomil + Placebo + losartan potassiumApproved

Prasugrel + ClopidogrelApproved

Diet+pravastatinApproved